Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress

To significantly enhance outcomes for TNBC patients, future research must concentrate on identifying predictive biomarkers and refining individualized therapy plans.

Authors

Institutions

Publication Details

Journal
Anti-Cancer Agents in Medicinal Chemistry
Published
2026-01-21
DOI
https://doi.org/10.2174/0118715206402646251115102627
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress

Viney Lather, Amiya Das
Anti-Cancer Agents in Medicinal Chemistry
HER2/EGFR in Cancer Research
article

Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress

Viney Lather, Amiya Das
article en

Abstract

To significantly enhance outcomes for TNBC patients, future research must concentrate on identifying predictive biomarkers and refining individualized therapy plans.

Anti-Cancer Agents in Medicinal ChemistryVol. 26
SRM Institute of Science and Technology (IN), Amity University (IN)
Good health and well-being
Openalex Percentile: Top 76%
HER2/EGFR in Cancer Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress — Viney Lather, Amiya Das · Anti-Cancer Agents in Medicinal Chemistry (2026) | TGRS Research Map | TGRS